12:03:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2023-12-05 11:15:46

In the International Journal of Molecular Science (https://www.mdpi.com/1422-0067/24/23/16705), Attana and Linnaeus University have published the validation of Attana's QCM technology for IgG detection and determination for in-vitro diagnostics. The technique has been validated against electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). The results in this publication are an important part in the development of Attana's immunity profiles.

In the publication Quartz Crystal Microbalance Platform for SARS-CoV-2 Immuno-Diagnostics, Attana's QCM technology has been evaluated for reproducibility, sensitivity, linearity, and specificity for detection of SARS-CoV-2 antibody binding. The results have been compared with ECLIA and CLIA. A total of 119 human serum samples were compared, of which 59 were positive with ECLIA, 52 with CLIA and 48 with QCM. In conclusion, the QCM-based SARS-CoV-2 IgG immunoassay showed high reproducibility and linearity, as well as good coherence with the reference methods.

Factors that affect the results are partly experiment-dependent and partly interaction-dependent. Experiment dependence is, for example, that the different techniques used different types of antigens, QCM S-antigen, ECLIA N-antigen and CLIA S- and N-antigen and different incubation times. QCM measures in real time for two minutes (but has no direct incubation time), ECLIA has nine minutes incubation time and CLIA has a two-step incubation totaling 45 minutes including rinse step.

Interaction dependence is linked to biological properties such as the kinetics of the antibody-antigen interaction and the antibody titer. A low titer and fast association and dissociation rate will initially give higher signal than a low titer with slow kinetics. One of the advantages of real-time measurement in QCM is precisely that the kinetics are determined and thereby can provide additional diagnostic information, i.e. about the neutralizing capacity of the antibodies. Since the purpose of this article was to validate Attana's QCM technique against existing techniques, the kinetics are not included in the results, but they will be in a further publication.

In summary, this has laid the foundation for the current joint project led by Prof. Ian Nicholls at Linnaeus University (https://news.cision.com/attana/r/the-swedish-knowledge-foundation-has-granted-sek-12-million-to-a-project-concerning-individual-immun,c3825152)  (https://news.cision.com/attana/r/the-swedish-knowledge-foundation-has-granted-sek-12-million-to-a-project-concerning-individual-immun,c3825152)which aims to develop immunity profiles for more pathogens.

Related Publications:

https://www.nature.com/articles/s41467-020-20251-8

https://europepmc.org/article/med/29399414

https://www.nature.com/articles/s41467-023-42408-x

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457302/

https://www.frontiersin.org/articles/10.3389/fvets.2023.1243853/full